<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03793855</url>
  </required_header>
  <id_info>
    <org_study_id>NUGLIC</org_study_id>
    <nct_id>NCT03793855</nct_id>
  </id_info>
  <brief_title>Nutritional Strategy for Glycemic Control in Patients With Type 2 Diabetes Mellitus (NUGLIC)</brief_title>
  <official_title>Effectiveness of a Nutritional Strategy for Glycemic Control in Patients With Type 2 Diabetes Mellitus Users of a Public Health System: NUGLIC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adherence to a healthy dietary pattern is part of the self-care of patients with type 2&#xD;
      diabetes mellitus (T2DM), and may contribute substantially to therapeutic target goals and to&#xD;
      a better quality of life as well. However, not all nutritional recommendations aimed at these&#xD;
      patients are easily applicable in clinical practice. The primary objective of the study is to&#xD;
      evaluate the effectiveness of a nutritional strategy for glycemic control in patients with&#xD;
      T2DM users of a Public Health System after 6 months of follow-up. As secondary objectives, we&#xD;
      will evaluate the impact of the proposed strategy on self-care and on the quality of life of&#xD;
      the patients. In this randomized multicenter open-label randomized trial, 370 patients &gt;30&#xD;
      years old with T2DM, glycated hemoglobin (HbA1C) ≥7% at the moment of the screening and who&#xD;
      have not received or received nutritional counseling for at least 06 months will be enrolled.&#xD;
      Patients allocated to the control group will receive individualized dietary prescription&#xD;
      according to the guidelines of the Brazilian Society of Diabetes. Nutritional counseling in&#xD;
      the intervention group will be performed based on the quality of the diet, the Food Guide for&#xD;
      the Brazilian Population and concepts of mindfulness and mindful eating; all dietary guidance&#xD;
      will be based on feasible goals built together (patient and nutritionist), and no diet will&#xD;
      be prescribed for intervention group. In both groups, patients will receive glymeters for&#xD;
      residential self-monitoring of glycemic levels. On-site follow-up visits will be carried out&#xD;
      at 30, 60, 90, and 180 days (final consultation). At 120 and 150 days, participants in the&#xD;
      intervention group will receive motivational messages via e-mail or SMS (for these patients,&#xD;
      consultation of 30 days will be a group meeting). Laboratory tests (lipid and glycemic&#xD;
      profile, serum creatinine, serum sodium, urinary sodium, serum potassium, urinary potassium&#xD;
      and albuminuria) will be performed at baseline and 180 days; anthropometric indexes and blood&#xD;
      pressure will be also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1C</measure>
    <time_frame>6 months</time_frame>
    <description>Glycated hemoglobin, in %. Glycemic control will be considered if the participant decreases the medication during the study and maintains HbA1C at the end of the follow-up; or if the patient maintains the medication throughout the study and decreases HbA1C at the end of the follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>B-PAID</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life evaluated by the Brazilian version of the Problem Areas in Diabetes Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FG</measure>
    <time_frame>6 months</time_frame>
    <description>Fasting glucose, in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSCA</measure>
    <time_frame>6 months</time_frame>
    <description>Self-care evaluated by the Brazilian version of the Diabetes Self-Care Activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-c</measure>
    <time_frame>6 months</time_frame>
    <description>LDL cholesterol, in mg/dL; it will be obtained by the Martin´s mathematical formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-c</measure>
    <time_frame>6 months</time_frame>
    <description>HDL cholesterol, in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TC</measure>
    <time_frame>6 months</time_frame>
    <description>Total cholesterol, in md/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG</measure>
    <time_frame>6 months</time_frame>
    <description>Serum triglycerides, in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-c</measure>
    <time_frame>6 months</time_frame>
    <description>VLDL cholesterol, in mg/dL; it will be obtained by the mathematical formula TG/5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NHDL</measure>
    <time_frame>6 months</time_frame>
    <description>Non-HDL cholesterol, in mg/dL; it will be obtained by the mathematical formula TC - HDL-c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Castelli Index I</measure>
    <time_frame>6 months</time_frame>
    <description>Castelli Index I, obtained by the mathematical formula TC/HDL-c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Castelli Index II</measure>
    <time_frame>6 months</time_frame>
    <description>Castelli Index II, obtained by the mathematical formula LDL-c/HDL-c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP</measure>
    <time_frame>6 months</time_frame>
    <description>Systolic blood pressure, in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP</measure>
    <time_frame>6 months</time_frame>
    <description>Diastolic blood pressure, in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BW</measure>
    <time_frame>6 months</time_frame>
    <description>Body weight, in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WC</measure>
    <time_frame>6 months</time_frame>
    <description>Waist circumference, in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>6 months</time_frame>
    <description>Body mass index, in kg/m2; it will be obtained by the mathematical formula (BW/height*height)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Nutritional Strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary Prescription</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individualized dietary prescription according to the guidelines of the Brazilian Society of Diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutritional Strategy</intervention_name>
    <description>Counseling based on dietary goals and mindfulness techniques.</description>
    <arm_group_label>Nutritional Strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary Prescription</intervention_name>
    <description>Dietary prescription according to guidelines.</description>
    <arm_group_label>Dietary Prescription</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: &gt;30 years old with medical diagnosis of T2DM, glycated hemoglobin&#xD;
        (HbA1C) ≥7% at the moment of the screening and who have not received or received&#xD;
        nutritional counseling for at least 06 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with type 1 DM (T1DM), latent autoimmune diabetes in adults (LADA) or HbA1C ≥&#xD;
             12%;&#xD;
&#xD;
          -  Severe neuropathy;&#xD;
&#xD;
          -  Chronic kidney disease;&#xD;
&#xD;
          -  Active cancer or life expectancy &lt;6 months;&#xD;
&#xD;
          -  Chemical dependence or use of antipsychotic drugs;&#xD;
&#xD;
          -  Autoimmune disease or chronic use of steroids;&#xD;
&#xD;
          -  Gastroparesis;&#xD;
&#xD;
          -  Pregnancy, lactation, gestational DM;&#xD;
&#xD;
          -  Acute coronary syndrome (ACS) in the last 60 days;&#xD;
&#xD;
          -  Wheelchair users;&#xD;
&#xD;
          -  Extreme obesity (body mass index [BMI] ≥40kg/m²);&#xD;
&#xD;
          -  Cognitive, neurological or psychiatric condition that prevents participation in the&#xD;
             study;&#xD;
&#xD;
          -  Participation in other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aline Marcadenti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aline Marcadenti, PhD</last_name>
    <phone>(+55)11 30536611</phone>
    <phone_ext>3558</phone_ext>
    <email>amarcaden@hcor.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre Cavalcanti, PhD</last_name>
    <phone>(+55)11 30536611</phone>
    <phone_ext>8201</phone_ext>
    <email>abiasi@hcor.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Federal de Juiz de Fora</name>
      <address>
        <city>Governador Valadares</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Lavras</name>
      <address>
        <city>Lavras</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Livia Ferreira, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre - Universidade Federal do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Ciências da Saúde de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Estadual de Cardiologia Aloysio de Castro</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universidade Federal da Bahia</name>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane Sahade, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital do Coracao</name>
      <address>
        <city>São Paulo</city>
        <zip>04004-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline Marcadenti, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Viçosa</name>
      <address>
        <city>Viçosa</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefina Bressan, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

